# BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer

> **NCT06462001** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Nottingham University Hospitals NHS Trust** · enrollment: 500 (actual)

## Conditions studied

- Transitional Cell Carcinoma
- Transurethral Resection

## Interventions

- **BIOLOGICAL:** Bacillus Calmette-Guerin Vaccine Intravesical
- **DRUG:** Mitomycin

## Key facts

- **NCT ID:** NCT06462001
- **Lead sponsor:** Nottingham University Hospitals NHS Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-10
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2024-06-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06462001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06462001, "BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT06462001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*